Global Quantitative Transcriptome Analysis Market
Global Quantitative Transcriptome Analysis Market

Quantitative Transcriptome Analysis Comprehensive Study by Type (Medical Instruments, Consumables, Services), Application (Drug Discovery and Development, Cancer Research, Diagnosis, Disease Treatment), Techniques (RNA sequencing (RNA-Seq), Microarrays, Expressed Sequence Tag (EST) Method, Serial Analysis of Gene Expression (SAGE) Method), Dieses Class (Oncology, Neurology, Immunology, Others), End User (Biopharmaceutical and Biotechnology Industry, Diagnostics Laboratories, Cancer Research Laboratories, Academic Research) Players and Region - Global Market Outlook to 2026

Quantitative Transcriptome Analysis Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 219 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Quantitative Transcriptome Analysis Market?

The transcriptome is the complete collection of all RNA molecules found in a single cell, a population of cells, or a living organism. The quantitative transcriptome analysis market is gaining traction as a method for drug development and cancer research. Quantitative transcriptome analysis is expected to become more common in the future as the human disease becomes more complex.

The market study is being classified by Type (Medical Instruments, Consumables and Services), by Application (Drug Discovery and Development, Cancer Research, Diagnosis and Disease Treatment) and major geographies with country level break-up.

Illumina, Inc (United States), F. Hoffmann-La Roche Ltd. (Switzerland), BGI Genomics (China), Qiagen N.V. (Germany), Thermo Fisher Scientific Inc. (United States), Macrogen (South Korea), Agilent Technologies (United States), 10x Genomics (United States), Promega Corporation (United States), Bio-Rad Laboratories, Inc. (United States) and GE Healthcare (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Fluidigm Corporation (United States) and Merck & Co., Inc. (United States).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Quantitative Transcriptome Analysis market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Quantitative Transcriptome Analysis market by Type, Application and Region.

On the basis of geography, the market of Quantitative Transcriptome Analysis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Research and Development Activities for Novel Cancer Therapeutic
  • Rising Complex Human Disease

Market Trend
  • Technical Progress in Medical Industry

Restraints
  • Ethical and Scientific concern of Transcriptome Analysis

Opportunities
  • Higher Funding Allocations to the Drug Discovery
  • Increasing Use of Biosimilars to Treat Severe Disease

Challenges
  • Insufficient Skilled Personnel


In March 2017, Lexogen, a transcriptomics and next generation sequencing company, announces the start of its RNA-Seq service, which focuses on gene expression profiling using Lexogen’s proprietary QuantSeq technology.


Key Target Audience
New Entrants and Investors, Quantitative Transcriptome Analysis Providers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Medical Instruments
  • Consumables
  • Services
By Application
  • Drug Discovery and Development
  • Cancer Research
  • Diagnosis
  • Disease Treatment
By Techniques
  • RNA sequencing (RNA-Seq)
  • Microarrays
  • Expressed Sequence Tag (EST) Method
  • Serial Analysis of Gene Expression (SAGE) Method

By Dieses Class
  • Oncology
  • Neurology
  • Immunology
  • Others

By End User
  • Biopharmaceutical and Biotechnology Industry
  • Diagnostics Laboratories
  • Cancer Research Laboratories
  • Academic Research

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Research and Development Activities for Novel Cancer Therapeutic
      • 3.2.2. Rising Complex Human Disease
    • 3.3. Market Challenges
      • 3.3.1. Insufficient Skilled Personnel
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Quantitative Transcriptome Analysis, by Type, Application, Techniques, Dieses Class, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Quantitative Transcriptome Analysis (Value)
      • 5.2.1. Global Quantitative Transcriptome Analysis by: Type (Value)
        • 5.2.1.1. Medical Instruments
        • 5.2.1.2. Consumables
        • 5.2.1.3. Services
      • 5.2.2. Global Quantitative Transcriptome Analysis by: Application (Value)
        • 5.2.2.1. Drug Discovery and Development
        • 5.2.2.2. Cancer Research
        • 5.2.2.3. Diagnosis
        • 5.2.2.4. Disease Treatment
      • 5.2.3. Global Quantitative Transcriptome Analysis by: Techniques (Value)
        • 5.2.3.1. RNA sequencing (RNA-Seq)
        • 5.2.3.2. Microarrays
        • 5.2.3.3. Expressed Sequence Tag (EST) Method
        • 5.2.3.4. Serial Analysis of Gene Expression (SAGE) Method
      • 5.2.4. Global Quantitative Transcriptome Analysis by: Dieses Class (Value)
        • 5.2.4.1. Oncology
        • 5.2.4.2. Neurology
        • 5.2.4.3. Immunology
        • 5.2.4.4. Others
      • 5.2.5. Global Quantitative Transcriptome Analysis by: End User (Value)
        • 5.2.5.1. Biopharmaceutical and Biotechnology Industry
        • 5.2.5.2. Diagnostics Laboratories
        • 5.2.5.3. Cancer Research Laboratories
        • 5.2.5.4. Academic Research
      • 5.2.6. Global Quantitative Transcriptome Analysis Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Quantitative Transcriptome Analysis (Price)
      • 5.3.1. Global Quantitative Transcriptome Analysis by: Type (Price)
  • 6. Quantitative Transcriptome Analysis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Illumina, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BGI Genomics (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Qiagen N.V. (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Macrogen (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Agilent Technologies (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. 10x Genomics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Promega Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GE Healthcare (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Quantitative Transcriptome Analysis Sale, by Type, Application, Techniques, Dieses Class, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Quantitative Transcriptome Analysis (Value)
      • 7.2.1. Global Quantitative Transcriptome Analysis by: Type (Value)
        • 7.2.1.1. Medical Instruments
        • 7.2.1.2. Consumables
        • 7.2.1.3. Services
      • 7.2.2. Global Quantitative Transcriptome Analysis by: Application (Value)
        • 7.2.2.1. Drug Discovery and Development
        • 7.2.2.2. Cancer Research
        • 7.2.2.3. Diagnosis
        • 7.2.2.4. Disease Treatment
      • 7.2.3. Global Quantitative Transcriptome Analysis by: Techniques (Value)
        • 7.2.3.1. RNA sequencing (RNA-Seq)
        • 7.2.3.2. Microarrays
        • 7.2.3.3. Expressed Sequence Tag (EST) Method
        • 7.2.3.4. Serial Analysis of Gene Expression (SAGE) Method
      • 7.2.4. Global Quantitative Transcriptome Analysis by: Dieses Class (Value)
        • 7.2.4.1. Oncology
        • 7.2.4.2. Neurology
        • 7.2.4.3. Immunology
        • 7.2.4.4. Others
      • 7.2.5. Global Quantitative Transcriptome Analysis by: End User (Value)
        • 7.2.5.1. Biopharmaceutical and Biotechnology Industry
        • 7.2.5.2. Diagnostics Laboratories
        • 7.2.5.3. Cancer Research Laboratories
        • 7.2.5.4. Academic Research
      • 7.2.6. Global Quantitative Transcriptome Analysis Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Quantitative Transcriptome Analysis (Price)
      • 7.3.1. Global Quantitative Transcriptome Analysis by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Quantitative Transcriptome Analysis: by Type(USD Million)
  • Table 2. Quantitative Transcriptome Analysis Medical Instruments , by Region USD Million (2015-2020)
  • Table 3. Quantitative Transcriptome Analysis Consumables , by Region USD Million (2015-2020)
  • Table 4. Quantitative Transcriptome Analysis Services , by Region USD Million (2015-2020)
  • Table 5. Quantitative Transcriptome Analysis: by Application(USD Million)
  • Table 6. Quantitative Transcriptome Analysis Drug Discovery and Development , by Region USD Million (2015-2020)
  • Table 7. Quantitative Transcriptome Analysis Cancer Research , by Region USD Million (2015-2020)
  • Table 8. Quantitative Transcriptome Analysis Diagnosis , by Region USD Million (2015-2020)
  • Table 9. Quantitative Transcriptome Analysis Disease Treatment , by Region USD Million (2015-2020)
  • Table 10. Quantitative Transcriptome Analysis: by Techniques(USD Million)
  • Table 11. Quantitative Transcriptome Analysis RNA sequencing (RNA-Seq) , by Region USD Million (2015-2020)
  • Table 12. Quantitative Transcriptome Analysis Microarrays , by Region USD Million (2015-2020)
  • Table 13. Quantitative Transcriptome Analysis Expressed Sequence Tag (EST) Method , by Region USD Million (2015-2020)
  • Table 14. Quantitative Transcriptome Analysis Serial Analysis of Gene Expression (SAGE) Method , by Region USD Million (2015-2020)
  • Table 15. Quantitative Transcriptome Analysis: by Dieses Class(USD Million)
  • Table 16. Quantitative Transcriptome Analysis Oncology , by Region USD Million (2015-2020)
  • Table 17. Quantitative Transcriptome Analysis Neurology , by Region USD Million (2015-2020)
  • Table 18. Quantitative Transcriptome Analysis Immunology , by Region USD Million (2015-2020)
  • Table 19. Quantitative Transcriptome Analysis Others , by Region USD Million (2015-2020)
  • Table 20. Quantitative Transcriptome Analysis: by End User(USD Million)
  • Table 21. Quantitative Transcriptome Analysis Biopharmaceutical and Biotechnology Industry , by Region USD Million (2015-2020)
  • Table 22. Quantitative Transcriptome Analysis Diagnostics Laboratories , by Region USD Million (2015-2020)
  • Table 23. Quantitative Transcriptome Analysis Cancer Research Laboratories , by Region USD Million (2015-2020)
  • Table 24. Quantitative Transcriptome Analysis Academic Research , by Region USD Million (2015-2020)
  • Table 25. South America Quantitative Transcriptome Analysis, by Country USD Million (2015-2020)
  • Table 26. South America Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 27. South America Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 28. South America Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 29. South America Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 30. South America Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 31. Brazil Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 32. Brazil Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 33. Brazil Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 34. Brazil Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 35. Brazil Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 36. Argentina Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 37. Argentina Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 38. Argentina Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 39. Argentina Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 40. Argentina Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 41. Rest of South America Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 42. Rest of South America Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 43. Rest of South America Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 44. Rest of South America Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 45. Rest of South America Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 46. Asia Pacific Quantitative Transcriptome Analysis, by Country USD Million (2015-2020)
  • Table 47. Asia Pacific Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 48. Asia Pacific Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 49. Asia Pacific Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 50. Asia Pacific Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 51. Asia Pacific Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 52. China Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 53. China Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 54. China Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 55. China Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 56. China Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 57. Japan Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 58. Japan Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 59. Japan Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 60. Japan Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 61. Japan Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 62. India Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 63. India Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 64. India Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 65. India Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 66. India Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 67. South Korea Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 68. South Korea Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 69. South Korea Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 70. South Korea Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 71. South Korea Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 72. Taiwan Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 73. Taiwan Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 74. Taiwan Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 75. Taiwan Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 76. Taiwan Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 77. Australia Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 78. Australia Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 79. Australia Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 80. Australia Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 81. Australia Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 86. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 87. Europe Quantitative Transcriptome Analysis, by Country USD Million (2015-2020)
  • Table 88. Europe Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 89. Europe Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 90. Europe Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 91. Europe Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 92. Europe Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 93. Germany Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 94. Germany Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 95. Germany Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 96. Germany Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 97. Germany Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 98. France Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 99. France Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 100. France Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 101. France Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 102. France Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 103. Italy Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 104. Italy Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 105. Italy Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 106. Italy Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 107. Italy Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 108. United Kingdom Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 109. United Kingdom Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 110. United Kingdom Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 111. United Kingdom Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 112. United Kingdom Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 113. Netherlands Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 114. Netherlands Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 115. Netherlands Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 116. Netherlands Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 117. Netherlands Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 118. Rest of Europe Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 119. Rest of Europe Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 120. Rest of Europe Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 121. Rest of Europe Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 122. Rest of Europe Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 123. MEA Quantitative Transcriptome Analysis, by Country USD Million (2015-2020)
  • Table 124. MEA Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 125. MEA Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 126. MEA Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 127. MEA Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 128. MEA Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 129. Middle East Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 130. Middle East Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 131. Middle East Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 132. Middle East Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 133. Middle East Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 134. Africa Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 135. Africa Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 136. Africa Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 137. Africa Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 138. Africa Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 139. North America Quantitative Transcriptome Analysis, by Country USD Million (2015-2020)
  • Table 140. North America Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 141. North America Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 142. North America Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 143. North America Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 144. North America Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 145. United States Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 146. United States Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 147. United States Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 148. United States Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 149. United States Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 150. Canada Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 151. Canada Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 152. Canada Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 153. Canada Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 154. Canada Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 155. Mexico Quantitative Transcriptome Analysis, by Type USD Million (2015-2020)
  • Table 156. Mexico Quantitative Transcriptome Analysis, by Application USD Million (2015-2020)
  • Table 157. Mexico Quantitative Transcriptome Analysis, by Techniques USD Million (2015-2020)
  • Table 158. Mexico Quantitative Transcriptome Analysis, by Dieses Class USD Million (2015-2020)
  • Table 159. Mexico Quantitative Transcriptome Analysis, by End User USD Million (2015-2020)
  • Table 160. Quantitative Transcriptome Analysis: by Type(USD/Units)
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Quantitative Transcriptome Analysis: by Type(USD Million)
  • Table 173. Quantitative Transcriptome Analysis Medical Instruments , by Region USD Million (2021-2026)
  • Table 174. Quantitative Transcriptome Analysis Consumables , by Region USD Million (2021-2026)
  • Table 175. Quantitative Transcriptome Analysis Services , by Region USD Million (2021-2026)
  • Table 176. Quantitative Transcriptome Analysis: by Application(USD Million)
  • Table 177. Quantitative Transcriptome Analysis Drug Discovery and Development , by Region USD Million (2021-2026)
  • Table 178. Quantitative Transcriptome Analysis Cancer Research , by Region USD Million (2021-2026)
  • Table 179. Quantitative Transcriptome Analysis Diagnosis , by Region USD Million (2021-2026)
  • Table 180. Quantitative Transcriptome Analysis Disease Treatment , by Region USD Million (2021-2026)
  • Table 181. Quantitative Transcriptome Analysis: by Techniques(USD Million)
  • Table 182. Quantitative Transcriptome Analysis RNA sequencing (RNA-Seq) , by Region USD Million (2021-2026)
  • Table 183. Quantitative Transcriptome Analysis Microarrays , by Region USD Million (2021-2026)
  • Table 184. Quantitative Transcriptome Analysis Expressed Sequence Tag (EST) Method , by Region USD Million (2021-2026)
  • Table 185. Quantitative Transcriptome Analysis Serial Analysis of Gene Expression (SAGE) Method , by Region USD Million (2021-2026)
  • Table 186. Quantitative Transcriptome Analysis: by Dieses Class(USD Million)
  • Table 187. Quantitative Transcriptome Analysis Oncology , by Region USD Million (2021-2026)
  • Table 188. Quantitative Transcriptome Analysis Neurology , by Region USD Million (2021-2026)
  • Table 189. Quantitative Transcriptome Analysis Immunology , by Region USD Million (2021-2026)
  • Table 190. Quantitative Transcriptome Analysis Others , by Region USD Million (2021-2026)
  • Table 191. Quantitative Transcriptome Analysis: by End User(USD Million)
  • Table 192. Quantitative Transcriptome Analysis Biopharmaceutical and Biotechnology Industry , by Region USD Million (2021-2026)
  • Table 193. Quantitative Transcriptome Analysis Diagnostics Laboratories , by Region USD Million (2021-2026)
  • Table 194. Quantitative Transcriptome Analysis Cancer Research Laboratories , by Region USD Million (2021-2026)
  • Table 195. Quantitative Transcriptome Analysis Academic Research , by Region USD Million (2021-2026)
  • Table 196. South America Quantitative Transcriptome Analysis, by Country USD Million (2021-2026)
  • Table 197. South America Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 198. South America Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 199. South America Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 200. South America Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 201. South America Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 202. Brazil Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 203. Brazil Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 204. Brazil Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 205. Brazil Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 206. Brazil Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 207. Argentina Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 208. Argentina Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 209. Argentina Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 210. Argentina Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 211. Argentina Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 212. Rest of South America Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 213. Rest of South America Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 214. Rest of South America Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 215. Rest of South America Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 216. Rest of South America Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 217. Asia Pacific Quantitative Transcriptome Analysis, by Country USD Million (2021-2026)
  • Table 218. Asia Pacific Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 219. Asia Pacific Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 220. Asia Pacific Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 221. Asia Pacific Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 222. Asia Pacific Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 223. China Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 224. China Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 225. China Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 226. China Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 227. China Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 228. Japan Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 229. Japan Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 230. Japan Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 231. Japan Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 232. Japan Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 233. India Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 234. India Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 235. India Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 236. India Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 237. India Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 238. South Korea Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 239. South Korea Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 240. South Korea Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 241. South Korea Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 242. South Korea Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 243. Taiwan Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 244. Taiwan Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 245. Taiwan Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 246. Taiwan Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 247. Taiwan Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 248. Australia Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 249. Australia Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 250. Australia Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 251. Australia Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 252. Australia Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 253. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 254. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 255. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 256. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 257. Rest of Asia-Pacific Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 258. Europe Quantitative Transcriptome Analysis, by Country USD Million (2021-2026)
  • Table 259. Europe Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 260. Europe Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 261. Europe Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 262. Europe Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 263. Europe Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 264. Germany Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 265. Germany Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 266. Germany Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 267. Germany Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 268. Germany Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 269. France Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 270. France Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 271. France Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 272. France Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 273. France Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 274. Italy Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 275. Italy Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 276. Italy Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 277. Italy Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 278. Italy Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 279. United Kingdom Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 280. United Kingdom Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 281. United Kingdom Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 282. United Kingdom Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 283. United Kingdom Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 284. Netherlands Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 285. Netherlands Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 286. Netherlands Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 287. Netherlands Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 288. Netherlands Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 289. Rest of Europe Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 290. Rest of Europe Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 291. Rest of Europe Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 292. Rest of Europe Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 293. Rest of Europe Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 294. MEA Quantitative Transcriptome Analysis, by Country USD Million (2021-2026)
  • Table 295. MEA Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 296. MEA Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 297. MEA Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 298. MEA Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 299. MEA Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 300. Middle East Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 301. Middle East Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 302. Middle East Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 303. Middle East Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 304. Middle East Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 305. Africa Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 306. Africa Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 307. Africa Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 308. Africa Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 309. Africa Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 310. North America Quantitative Transcriptome Analysis, by Country USD Million (2021-2026)
  • Table 311. North America Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 312. North America Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 313. North America Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 314. North America Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 315. North America Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 316. United States Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 317. United States Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 318. United States Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 319. United States Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 320. United States Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 321. Canada Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 322. Canada Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 323. Canada Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 324. Canada Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 325. Canada Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 326. Mexico Quantitative Transcriptome Analysis, by Type USD Million (2021-2026)
  • Table 327. Mexico Quantitative Transcriptome Analysis, by Application USD Million (2021-2026)
  • Table 328. Mexico Quantitative Transcriptome Analysis, by Techniques USD Million (2021-2026)
  • Table 329. Mexico Quantitative Transcriptome Analysis, by Dieses Class USD Million (2021-2026)
  • Table 330. Mexico Quantitative Transcriptome Analysis, by End User USD Million (2021-2026)
  • Table 331. Quantitative Transcriptome Analysis: by Type(USD/Units)
  • Table 332. Research Programs/Design for This Report
  • Table 333. Key Data Information from Secondary Sources
  • Table 334. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Quantitative Transcriptome Analysis: by Type USD Million (2015-2020)
  • Figure 5. Global Quantitative Transcriptome Analysis: by Application USD Million (2015-2020)
  • Figure 6. Global Quantitative Transcriptome Analysis: by Techniques USD Million (2015-2020)
  • Figure 7. Global Quantitative Transcriptome Analysis: by Dieses Class USD Million (2015-2020)
  • Figure 8. Global Quantitative Transcriptome Analysis: by End User USD Million (2015-2020)
  • Figure 9. South America Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 10. Asia Pacific Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 11. Europe Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 12. MEA Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 13. North America Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 14. Global Quantitative Transcriptome Analysis: by Type USD/Units (2015-2020)
  • Figure 15. Global Quantitative Transcriptome Analysis share by Players 2020 (%)
  • Figure 16. Global Quantitative Transcriptome Analysis share by Players (Top 3) 2020(%)
  • Figure 17. Global Quantitative Transcriptome Analysis share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Illumina, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. Illumina, Inc (United States) Revenue: by Geography 2020
  • Figure 21. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 23. BGI Genomics (China) Revenue, Net Income and Gross profit
  • Figure 24. BGI Genomics (China) Revenue: by Geography 2020
  • Figure 25. Qiagen N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Qiagen N.V. (Germany) Revenue: by Geography 2020
  • Figure 27. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Macrogen (South Korea) Revenue, Net Income and Gross profit
  • Figure 30. Macrogen (South Korea) Revenue: by Geography 2020
  • Figure 31. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 32. Agilent Technologies (United States) Revenue: by Geography 2020
  • Figure 33. 10x Genomics (United States) Revenue, Net Income and Gross profit
  • Figure 34. 10x Genomics (United States) Revenue: by Geography 2020
  • Figure 35. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Promega Corporation (United States) Revenue: by Geography 2020
  • Figure 37. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 40. GE Healthcare (United States) Revenue: by Geography 2020
  • Figure 41. Global Quantitative Transcriptome Analysis: by Type USD Million (2021-2026)
  • Figure 42. Global Quantitative Transcriptome Analysis: by Application USD Million (2021-2026)
  • Figure 43. Global Quantitative Transcriptome Analysis: by Techniques USD Million (2021-2026)
  • Figure 44. Global Quantitative Transcriptome Analysis: by Dieses Class USD Million (2021-2026)
  • Figure 45. Global Quantitative Transcriptome Analysis: by End User USD Million (2021-2026)
  • Figure 46. South America Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 47. Asia Pacific Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 48. Europe Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 49. MEA Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 50. North America Quantitative Transcriptome Analysis Share (%), by Country
  • Figure 51. Global Quantitative Transcriptome Analysis: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Illumina, Inc (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • BGI Genomics (China)
  • Qiagen N.V. (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Macrogen (South Korea)
  • Agilent Technologies (United States)
  • 10x Genomics (United States)
  • Promega Corporation (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • GE Healthcare (United States)
Additional players considered in the study are as follows:
Fluidigm Corporation (United States) , Merck & Co., Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation